Advanced search
Publication Cover
Postgraduate Medicine Volume 111, 2002 - Issue 5
Submit an article Journal homepage
14
Views
14
CrossRef citations to date
0
Altmetric
Original Articles

Current oral agents for type 2 diabetes

Many options, but which to choose when?

Andrew J. Ahmann Dr Ahmann is associate professor of medicine and Dr Riddle is professor of medicine, division of endocrinology, diabetes, and clinical nutrition, Oregon Health and Science University School of Medicine, Portland.Correspondence[email protected]
, MD &
Matthew C. Riddle Dr Ahmann is associate professor of medicine and Dr Riddle is professor of medicine, division of endocrinology, diabetes, and clinical nutrition, Oregon Health and Science University School of Medicine, Portland.
, MD
Pages 32-46 | Published online: 30 Jun 2015

References

  • Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990–1998. Diabetes Care 2000; 23(9): 1278–83
  • American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998; 21(2): 296–309
  • DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131(4): 281–303
  • Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. Seminars in Medicine of the Beth Israel Hospital, Boston. N Engl J Med 1996; 334(12): 777–83
  • Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405–12
  • Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997; 26(3): 511–22
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–53
  • Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21(11): 1897–903
  • Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23(11): 1660–5
  • Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997; 26(3): 539–52
  • Johansen K. Efficacy of metformin in the treatment of NIDDM: metaanalysis. Diabetes Care 1999; 22(1): 33–7
  • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–65
  • Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22(10): 1151–68
  • Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60(2): 333–43
  • Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypo-glycemic effects of thiazolidinediones. Ann Intern Med 2001; 134(1): 61–71
  • Khan MA, St Peter JV, Neafus KL, et al. A prospective, randomized comparison of the metabolic effects of pioglitazone vs rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. (Abstr) Diabetes 2001; 50(Suppl 2): A119
  • Thomas JC, Taylor KB. Effects of thiazolidinediones on lipoprotein subclasses in patients who are insulin resistant. (Abstr) Diabetes 2001; 50(Suppl 2): A455
  • Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281 (21): 2005–12
  • Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24(4): 758–67
  • Mensing C, Boucher J, Cypress M, et al. National standards for diabetes self-management education. Diabetes Care 2001; 24(Suppl 1): S126
  • American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001; 24(4): 775–8
  • Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001; 24(8): 1460–7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.